MX2009008750A - Terapia de vacuna para neovascularizacion coroidal. - Google Patents
Terapia de vacuna para neovascularizacion coroidal.Info
- Publication number
- MX2009008750A MX2009008750A MX2009008750A MX2009008750A MX2009008750A MX 2009008750 A MX2009008750 A MX 2009008750A MX 2009008750 A MX2009008750 A MX 2009008750A MX 2009008750 A MX2009008750 A MX 2009008750A MX 2009008750 A MX2009008750 A MX 2009008750A
- Authority
- MX
- Mexico
- Prior art keywords
- neovascularization
- peptide
- choroidal neovascularization
- vaccine therapy
- choroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se intenta determinar la presencia o ausencia de la efectividad de la vacunación con un péptido derivado de VEGFR-2, el cual es conocido como una de las proteínas implicadas en la neovascularización, administrando el péptido a un ratón modelo con la capacidad de expresar HLA-A*0201 humano (un ratón transgénico A2/Kb). Como resultado, se descubrió que una vacuna que contiene el péptido como un antígeno, es efectivo en la inhibición de la neovascularización en un coroide. Por lo tanto, se describe una vacuna para el tratamiento o prevención, o ambos, de una enfermedad inducida mediante la neovascularización en un coroide (maculopatía neovascular), que comprende un péptido derivado de VEGFR-2 en la forma de un ingrediente activo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007036318 | 2007-02-16 | ||
| PCT/JP2008/052487 WO2008099908A1 (ja) | 2007-02-16 | 2008-02-15 | 脈絡膜新生血管のワクチン療法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009008750A true MX2009008750A (es) | 2009-08-27 |
Family
ID=39690133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009008750A MX2009008750A (es) | 2007-02-16 | 2008-02-15 | Terapia de vacuna para neovascularizacion coroidal. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100297157A1 (es) |
| EP (1) | EP2119447B1 (es) |
| JP (1) | JP5470558B2 (es) |
| KR (1) | KR101493775B1 (es) |
| CN (2) | CN101678065A (es) |
| AU (1) | AU2008215432B2 (es) |
| BR (1) | BRPI0807654A2 (es) |
| CA (1) | CA2678432A1 (es) |
| ES (1) | ES2405763T3 (es) |
| HK (1) | HK1134449A1 (es) |
| IL (1) | IL200177A0 (es) |
| MX (1) | MX2009008750A (es) |
| PL (1) | PL2119447T3 (es) |
| RU (2) | RU2481118C2 (es) |
| SG (1) | SG178793A1 (es) |
| WO (1) | WO2008099908A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2267021T3 (en) | 2002-09-12 | 2015-03-30 | Oncotherapy Science Inc | KDR peptides and vaccines comprising the same |
| TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| TW201109029A (en) * | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861301A (en) * | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
| CN1318447C (zh) | 1998-06-25 | 2007-05-30 | 伊东恭悟 | 得自亲环蛋白b的肿瘤抗原肽 |
| WO2003028643A2 (en) * | 2001-10-01 | 2003-04-10 | Targesome, Inc. | Targeted therapeutic lipid constructs having cell surface targets |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| DK2267021T3 (en) * | 2002-09-12 | 2015-03-30 | Oncotherapy Science Inc | KDR peptides and vaccines comprising the same |
| ES2428354T3 (es) * | 2002-09-18 | 2013-11-07 | Trustees Of The University Of Pennsylvania | Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea |
| US7962316B2 (en) * | 2003-10-27 | 2011-06-14 | Merck Sharp & Dohme Corp. | Method of designing siRNAs for gene silencing |
| EP1855707B1 (en) * | 2005-02-28 | 2012-04-04 | Oncotherapy Science, Inc. | Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides |
| KR100855012B1 (ko) * | 2007-12-03 | 2008-08-28 | 조용래 | 여과 집진기용 탈리장치 |
| TW201109029A (en) * | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
-
2008
- 2008-02-15 JP JP2008558141A patent/JP5470558B2/ja not_active Expired - Fee Related
- 2008-02-15 CN CN200880012298A patent/CN101678065A/zh active Pending
- 2008-02-15 PL PL08711317T patent/PL2119447T3/pl unknown
- 2008-02-15 US US12/526,626 patent/US20100297157A1/en not_active Abandoned
- 2008-02-15 CN CN201310717200.4A patent/CN103784938A/zh active Pending
- 2008-02-15 BR BRPI0807654-5A2A patent/BRPI0807654A2/pt not_active IP Right Cessation
- 2008-02-15 MX MX2009008750A patent/MX2009008750A/es active IP Right Grant
- 2008-02-15 EP EP08711317A patent/EP2119447B1/en not_active Not-in-force
- 2008-02-15 KR KR1020097018615A patent/KR101493775B1/ko not_active IP Right Cessation
- 2008-02-15 SG SG2012010914A patent/SG178793A1/en unknown
- 2008-02-15 ES ES08711317T patent/ES2405763T3/es active Active
- 2008-02-15 WO PCT/JP2008/052487 patent/WO2008099908A1/ja active Application Filing
- 2008-02-15 RU RU2009134539/15A patent/RU2481118C2/ru not_active IP Right Cessation
- 2008-02-15 CA CA002678432A patent/CA2678432A1/en not_active Abandoned
- 2008-02-15 AU AU2008215432A patent/AU2008215432B2/en not_active Ceased
-
2009
- 2009-07-30 IL IL200177A patent/IL200177A0/en unknown
-
2010
- 2010-03-10 HK HK10102499.0A patent/HK1134449A1/en not_active IP Right Cessation
-
2013
- 2013-01-25 RU RU2013103487/15A patent/RU2013103487A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101678065A (zh) | 2010-03-24 |
| PL2119447T3 (pl) | 2013-08-30 |
| EP2119447B1 (en) | 2013-04-03 |
| RU2009134539A (ru) | 2011-03-27 |
| AU2008215432A1 (en) | 2008-08-21 |
| RU2013103487A (ru) | 2014-07-27 |
| EP2119447A1 (en) | 2009-11-18 |
| AU2008215432A2 (en) | 2009-11-05 |
| JPWO2008099908A1 (ja) | 2010-05-27 |
| US20100297157A1 (en) | 2010-11-25 |
| WO2008099908A1 (ja) | 2008-08-21 |
| IL200177A0 (en) | 2010-04-15 |
| RU2481118C2 (ru) | 2013-05-10 |
| SG178793A1 (en) | 2012-03-29 |
| EP2119447A4 (en) | 2010-05-19 |
| ES2405763T3 (es) | 2013-06-03 |
| CN103784938A (zh) | 2014-05-14 |
| HK1134449A1 (en) | 2010-04-30 |
| KR101493775B1 (ko) | 2015-02-16 |
| AU2008215432B2 (en) | 2013-03-21 |
| JP5470558B2 (ja) | 2014-04-16 |
| BRPI0807654A2 (pt) | 2014-06-03 |
| KR20090115801A (ko) | 2009-11-06 |
| CA2678432A1 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| MX2019012884A (es) | Terapia de combinacion. | |
| NZ630589A (en) | Methods of treating alzheimer’s disease and pharmaceutical compositions thereof | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| SG178954A1 (en) | Immunogenic compositions including tlr activity modulators | |
| EA200701519A1 (ru) | Живая аттенуированная ротавирусная вакцина для перорального введения | |
| MX2021008224A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
| MX2012002654A (es) | Compuestos y composiciones como moduladores de la actividad de tlr. | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| NO20070702L (no) | Kombinasjonsbehandling for ikke-hematologisk malignitet ved anvendelse av anti-OGF-1R antistoff | |
| JP2011518170A5 (es) | ||
| NO20084199L (no) | Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom | |
| MX2007001679A (es) | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. | |
| CY1114688T1 (el) | Ενα γαλακτωμα τυπου νερου μεσα σε λαδι για την θεραπεια μιας ασθενειας του ματιου | |
| WO2005051429A3 (en) | Targeted conjugates with a modified saccharide linker | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
| JP2018524306A5 (es) | ||
| MX2009008750A (es) | Terapia de vacuna para neovascularizacion coroidal. | |
| WO2004014367A3 (en) | Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease | |
| JP2019529569A5 (es) | ||
| AR048671A1 (es) | Procedimiento de vacunacion contra la infeccion testicular por bvdv | |
| MX2011012659A (es) | Terapia con vacunas para neovascularizacion coroidea. | |
| CL2020000124A1 (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |